Semaglutide
A long-acting GLP-1 receptor agonist approved in injectable form for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and in oral form (Rybelsus). It is among the most extensively studied molecules in the peptide space.
Retatrutide
An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 results reported some of the largest weight reductions yet seen with an incretin-based agent, and a phase 3 program is ongoing.
Mechanism
Semaglutide is a selective GLP-1 receptor agonist. Retatrutide adds GIP and glucagon receptor activity, hypothesizing additional effects on energy expenditure and fat oxidation. Triple agonism is the most ambitious mechanism in the incretin field.
Trial results
Semaglutide’s STEP 1 reported 14.9% mean weight reduction at 68 weeks. Retatrutide’s phase 2 reported approximately 17.5% at 24 weeks with continued loss to 48 weeks at the highest dose. The retatrutide numbers are striking — and come from a single phase 2 trial population.
Status
Semaglutide is approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in indicated populations. Retatrutide is in phase 3. It is not a medicine; it is a candidate.
Safety
Semaglutide’s profile is defined by years of class experience and enormous exposure. Retatrutide’s known profile so far is dominated by dose-related GI effects with open long-term questions. The triple mechanism’s novelty means less class experience to lean on.
The honest framing
If retatrutide’s phase 3 confirms the phase 2 signal, it may become a leading medicine. Until then, every confident claim about its superiority is a prediction dressed as a result.
Frequently Asked Questions
Is retatrutide approved anywhere?
No. It is investigational everywhere. Sales listings for it are by definition outside the regulated supply system.
Why do people compare it to semaglutide already?
Because its phase 2 numbers exceeded semaglutide’s registrational averages — an interesting cross-trial signal, not a head-to-head result.
Does more receptor activity mean more risk?
Not necessarily — but it does mean less accumulated human experience, which is its own kind of risk while the compound is still in trials.
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.